Holen Sie sich die Stockscreener-App
26.33
8.97%
-2.4927
Schlusskurs vom Vortag:
$28.82
Offen:
$28.26
24-Stunden-Volumen:
222.88K
Relative Volume:
0.77
Marktkapitalisierung:
$1.18B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-13.34%
1M Leistung:
+7.36%
6M Leistung:
+81.84%
1J Leistung:
+342.50%
1-Tages-Spanne:
$25.98
$28.26
1-Wochen-Bereich:
$25.98
$30.33
52-Wochen-Spanne:
$4.66
$32.63
Septerna Inc Stock (SEPN) Company Profile
Firmenname
Septerna Inc
Sektor
Branche
Telefon
650-338-3533
Adresse
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
26.41 | 1.29B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.11 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.98 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.91 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.83 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-15 | Eingeleitet | Truist | Buy |
| 2025-11-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-11-19 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-19 | Eingeleitet | TD Cowen | Buy |
| 2024-11-19 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Septerna Inc Aktie (SEPN) Neueste Nachrichten
Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells 70,453 Shares of Stock - MarketBeat
SEPN: SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials - TradingView
SEPN: SEP-631 and SEP-479 advance with strong data, phase 2 and 1 trials planned, and pipeline growth - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Payoneer (PAYO) and Porch Group (PRCH) - The Globe and Mail
A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment - Sahm
Septerna (SEPN) Receives Overweight Rating and Target Price Hike by Wells Fargo | SEPN Stock News - GuruFocus
Wells Fargo & Company Increases Septerna (NASDAQ:SEPN) Price Target to $48.00 - MarketBeat
[144] Septerna, Inc. SEC Filing - Stock Titan
Septerna (NASDAQ:SEPN) Price Target Raised to $40.00 at HC Wainwright - MarketBeat
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Septerna Advances SEP-631 After Positive Phase 1 Results - TipRanks
SEPN: SEP-631 showed strong Phase 1 efficacy and safety, advancing to Phase 2 for urticaria in 2026 - TradingView
Septerna reports positive Phase 1 SEP-631 data; plans Phase 2b CSU study in 2H 2026 - TradingView
Positive SEP-631 trial data drives Phase 2 plan at Septerna (NASDAQ: SEPN) - Stock Titan
Septerna’s SEP-631 shows positive Phase 1 trial results - Investing.com Australia
Septerna’s SEP-631 shows positive Phase 1 trial results By Investing.com - Investing.com South Africa
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy - Bitget
Septerna says SEP-631 well-tolerated with adverse event profile comparable to placebo - marketscreener.com
Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo - TradingView
Septerna pill blocked induced skin wheals at low doses in Phase 1 test - Stock Titan
Sentiment Watch: Is Septerna Inc part of any ETFBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Why Septerna (SEPN) Is Up 6.4% After Surging GPCR Pipeline-Driven Revenue GrowthAnd What's Next - simplywall.st
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Septerna, Inc. (SEPN) Stock Analysis: Unleashing a 12,113% Revenue Growth Amidst Biotech Innovations - DirectorsTalk Interviews
Zacks Research Upgrades Septerna (NASDAQ:SEPN) to Hold - MarketBeat
Aug Breakouts: Does Septerna Inc have a sustainable dividendMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Septerna stock reaches all-time high at 31.39 USD By Investing.com - Investing.com Australia
Septerna (NASDAQ:SEPN) Reaches New 12-Month HighStill a Buy? - MarketBeat
SEP-631 Phase 1 Readout: The Catalyst Set To Drive Septerna In 2026 (NASDAQ:SEPN) - Seeking Alpha
Septerna stock reaches all-time high at 31.39 USD - Investing.com
Will Septerna Inc outperform the market in YEAR2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Septerna to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Biotech Septerna to webcast TD Cowen health talk on March 3 - Stock Titan
SEPNSepterna, Inc. Latest Stock News & Market Updates - Stock Titan
Septerna president Bhatt sells $115,860 in shares By Investing.com - Investing.com South Africa
Septerna, Inc. (SEPN) Stock Analysis: A Biotech Powerhouse With A 25% Upside Potential - DirectorsTalk Interviews
Septerna president Bhatt sells $115,860 in shares - Investing.com Nigeria
Insider Selling: Septerna (NASDAQ:SEPN) COO Sells 4,000 Shares of Stock - MarketBeat
Will Septerna Inc. announce a stock split2025 Technical Overview & Accurate Intraday Trading Signals - mfd.ru
Septerna (NASDAQ:SEPN) Trading Down 5.9%Here's What Happened - MarketBeat
Will Septerna Inc. stock return to pre crisis levelsMarket Growth Report & Accurate Entry and Exit Point Alerts - mfd.ru
Insiders See US$934.3k Investment In Septerna Jump Last Week - 富途牛牛
Septerna (NASDAQ:SEPN) Hits New 1-Year HighWhat's Next? - MarketBeat
Septerna Inc stock hits all-time high at 30.51 USD By Investing.com - Investing.com Canada
Septerna Inc stock hits all-time high at 30.51 USD - Investing.com India
Septerna (NASDAQ:SEPN) Shares Up 9.4%Here's What Happened - MarketBeat
Risk Analysis: How volatile is Septerna Inc stockPortfolio Growth Summary & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Investment Recap: Is Septerna Inc forming a bullish divergenceNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
Published on: 2026-02-21 01:46:34 - mfd.ru
Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Pioneer With 31.43% Upside Potential - DirectorsTalk Interviews
Loss Report: Does Septerna Inc have a sustainable dividendMarket Risk Analysis & Safe Entry Point Alerts - baoquankhu1.vn
Finanzdaten der Septerna Inc-Aktie (SEPN)
Es liegen keine Finanzdaten für Septerna Inc (SEPN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):